396 related articles for article (PubMed ID: 33672813)
21. Tumor delivery of macromolecular drugs based on the EPR effect.
Torchilin V
Adv Drug Deliv Rev; 2011 Mar; 63(3):131-5. PubMed ID: 20304019
[TBL] [Abstract][Full Text] [Related]
22. Employment of enhanced permeability and retention effect (EPR): Nanoparticle-based precision tools for targeting of therapeutic and diagnostic agent in cancer.
Kalyane D; Raval N; Maheshwari R; Tambe V; Kalia K; Tekade RK
Mater Sci Eng C Mater Biol Appl; 2019 May; 98():1252-1276. PubMed ID: 30813007
[TBL] [Abstract][Full Text] [Related]
23. Pharmacological and physical vessel modulation strategies to improve EPR-mediated drug targeting to tumors.
Ojha T; Pathak V; Shi Y; Hennink WE; Moonen CTW; Storm G; Kiessling F; Lammers T
Adv Drug Deliv Rev; 2017 Sep; 119():44-60. PubMed ID: 28697952
[TBL] [Abstract][Full Text] [Related]
24. Targeting endothelial permeability in the EPR effect.
Lahooti B; Akwii RG; Zahra FT; Sajib MS; Lamprou M; Alobaida A; Lionakis MS; Mattheolabakis G; Mikelis CM
J Control Release; 2023 Sep; 361():212-235. PubMed ID: 37517543
[TBL] [Abstract][Full Text] [Related]
25. Strategies to improve the EPR effect: A mechanistic perspective and clinical translation.
Ikeda-Imafuku M; Wang LL; Rodrigues D; Shaha S; Zhao Z; Mitragotri S
J Control Release; 2022 May; 345():512-536. PubMed ID: 35337939
[TBL] [Abstract][Full Text] [Related]
26. Augmentation of EPR Effect and Efficacy of Anticancer Nanomedicine by Carbon Monoxide Generating Agents.
Fang J; Islam R; Islam W; Yin H; Subr V; Etrych T; Ulbrich K; Maeda H
Pharmaceutics; 2019 Jul; 11(7):. PubMed ID: 31315251
[TBL] [Abstract][Full Text] [Related]
27. Enhancing the Accumulation of Polymer Micelles by Selectively Dilating Tumor Blood Vessels with NO for Highly Effective Cancer Treatment.
Wei G; Wang Y; Huang X; Yang G; Zhao J; Zhou S
Adv Healthc Mater; 2018 Dec; 7(24):e1801094. PubMed ID: 30565900
[TBL] [Abstract][Full Text] [Related]
28. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect.
Fang J; Nakamura H; Maeda H
Adv Drug Deliv Rev; 2011 Mar; 63(3):136-51. PubMed ID: 20441782
[TBL] [Abstract][Full Text] [Related]
29. Polysaccharide-based nanocarriers for efficient transvascular drug delivery.
Zhang M; Ma H; Wang X; Yu B; Cong H; Shen Y
J Control Release; 2023 Feb; 354():167-187. PubMed ID: 36581260
[TBL] [Abstract][Full Text] [Related]
30. Destruction of tumor vasculature by vascular disrupting agents in overcoming the limitation of EPR effect.
Liu Z; Zhang Y; Shen N; Sun J; Tang Z; Chen X
Adv Drug Deliv Rev; 2022 Apr; 183():114138. PubMed ID: 35143895
[TBL] [Abstract][Full Text] [Related]
31. Electrochemotherapy of Deep-Seated Tumors: State of Art and Perspectives as Possible "EPR Effect Enhancer" to Improve Cancer Nanomedicine Efficacy.
Bonferoni MC; Rassu G; Gavini E; Sorrenti M; Catenacci L; Torre ML; Perteghella S; Ansaloni L; Maestri M; Giunchedi P
Cancers (Basel); 2021 Sep; 13(17):. PubMed ID: 34503247
[TBL] [Abstract][Full Text] [Related]
32. Positron Emission Tomography Based Elucidation of the Enhanced Permeability and Retention Effect in Dogs with Cancer Using Copper-64 Liposomes.
Hansen AE; Petersen AL; Henriksen JR; Boerresen B; Rasmussen P; Elema DR; af Rosenschöld PM; Kristensen AT; Kjær A; Andresen TL
ACS Nano; 2015 Jul; 9(7):6985-95. PubMed ID: 26022907
[TBL] [Abstract][Full Text] [Related]
33. Nanodrug Delivery: Is the Enhanced Permeability and Retention Effect Sufficient for Curing Cancer?
Nakamura Y; Mochida A; Choyke PL; Kobayashi H
Bioconjug Chem; 2016 Oct; 27(10):2225-2238. PubMed ID: 27547843
[TBL] [Abstract][Full Text] [Related]
34. EPR-Effect Enhancers Strongly Potentiate Tumor-Targeted Delivery of Nanomedicines to Advanced Cancers: Further Extension to Enhancement of the Therapeutic Effect.
Islam W; Kimura S; Islam R; Harada A; Ono K; Fang J; Niidome T; Sawa T; Maeda H
J Pers Med; 2021 May; 11(6):. PubMed ID: 34071552
[TBL] [Abstract][Full Text] [Related]
35. An Updated Review on EPR-Based Solid Tumor Targeting Nanocarriers for Cancer Treatment.
Sharifi M; Cho WC; Ansariesfahani A; Tarharoudi R; Malekisarvar H; Sari S; Bloukh SH; Edis Z; Amin M; Gleghorn JP; Hagen TLMT; Falahati M
Cancers (Basel); 2022 Jun; 14(12):. PubMed ID: 35740534
[TBL] [Abstract][Full Text] [Related]
36. Histidine-rich glycoprotein-induced vascular normalization improves EPR-mediated drug targeting to and into tumors.
Theek B; Baues M; Gremse F; Pola R; Pechar M; Negwer I; Koynov K; Weber B; Barz M; Jahnen-Dechent W; Storm G; Kiessling F; Lammers T
J Control Release; 2018 Jul; 282():25-34. PubMed ID: 29730154
[TBL] [Abstract][Full Text] [Related]
37. Accumulating nanoparticles by EPR: A route of no return.
Ngoune R; Peters A; von Elverfeldt D; Winkler K; Pütz G
J Control Release; 2016 Sep; 238():58-70. PubMed ID: 27448444
[TBL] [Abstract][Full Text] [Related]
38. Liposomes of Quantum Dots Configured for Passive and Active Delivery to Tumor Tissue.
Aizik G; Waiskopf N; Agbaria M; Ben-David-Naim M; Levi-Kalisman Y; Shahar A; Banin U; Golomb G
Nano Lett; 2019 Sep; 19(9):5844-5852. PubMed ID: 31424944
[TBL] [Abstract][Full Text] [Related]
39. Monitoring EPR Effect Dynamics during Nanotaxane Treatment with Theranostic Polymeric Micelles.
Biancacci I; De Lorenzi F; Theek B; Bai X; May JN; Consolino L; Baues M; Moeckel D; Gremse F; von Stillfried S; El Shafei A; Benderski K; Azadkhah Shalmani A; Wang A; Momoh J; Peña Q; Buhl EM; Buyel J; Hennink W; Kiessling F; Metselaar J; Shi Y; Lammers T
Adv Sci (Weinh); 2022 Apr; 9(10):e2103745. PubMed ID: 35072358
[TBL] [Abstract][Full Text] [Related]
40. Parameters Affecting the Enhanced Permeability and Retention Effect: The Need for Patient Selection.
Natfji AA; Ravishankar D; Osborn HMI; Greco F
J Pharm Sci; 2017 Nov; 106(11):3179-3187. PubMed ID: 28669714
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
